Business News • PR NewsWire • Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy

Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy

Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy

STOCKHOLM, April 20, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Aβ Protofibril...

View More : https://www.prnewswire.com:443/news-releases/lecanemab-ban2401-phase-2b-study-in-early-alzheimers-disease-published-in-p...

Releted News by prnewswire

Concentric AB electric coolant pump selected for high power density engine with leading global OEM for off-highway vehicles

Leanna Haakons Share How to Take Some of the Stress Out of Tax Day With TipsOnTV

Chinafy Joins Alibaba Cloud Partner Network

Delivering Versatile Projection and Entertainment to Hybrid Working Pros, Epson Expands SMB Lineup

Cisco Commits $100 Million to Help Address Climate Crisis